Paper39802175
Myosin activator omecamtiv mecarbil exhibits divergent inotropic and lusitropic effects in cardiac slices from patients with heart failure.
Varzideh F and 6 others. J Mol Cell Cardiol Plus, 2023. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Myosin activator omecamtiv mecarbil exhibits divergent inotropic and lusitropic effects in cardiac slices from patients with heart failure. Papers, record 39802175. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39802175
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Myosin activator omecamtiv mecarbil exhibits divergent inotropic and lusitropic effects in cardiac slices from patients with heart failure.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References20
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35852527 | Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial. | JAMA | 2022 | https://conductscience.org/library/papers/35852527 | PubMed |
| 2 | 36556120 | Efficacy of the New Inotropic Agent Istaroxime in Acute Heart Failure. | J Clin Med | 2022 | https://conductscience.org/library/papers/36556120 | PubMed |
| 3 | 27914658 | Searching for the perfect agent to improve cardiac contractility. | Lancet | 2016 | https://conductscience.org/library/papers/27914658 | PubMed |
| 4 | 21415352 | Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. | Science | 2011 | https://conductscience.org/library/papers/21415352 | PubMed |
| 5 | 36082222 | Effects of omecamtiv mecarbil on the contractile properties of skinned porcine left atrial and ventricular muscles. | Front Physiol | 2022 | https://conductscience.org/library/papers/36082222 | PubMed |
| 6 | 34643642 | Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial. | JAMA Cardiol | 2022 | https://conductscience.org/library/papers/34643642 | PubMed |
| 7 | 36722665 | Omecamtiv mecarbil augments cardiomyocyte contractile activity both at resting and systolic Ca2+ levels. | ESC Heart Fail | 2023 | https://conductscience.org/library/papers/36722665 | PubMed |
| 8 | 21856480 | Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. | Lancet | 2011 | https://conductscience.org/library/papers/21856480 | PubMed |
| 9 | 34498676 | Advances in the understanding of excitation-contraction coupling: the pulsing quest for drugs against heart failure and arrhythmias. | Eur Heart J Cardiovasc Pharmacother | 2021 | https://conductscience.org/library/papers/34498676 | PubMed |
| 10 | 27012405 | Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. | J Am Coll Cardiol | 2016 | https://conductscience.org/library/papers/27012405 | PubMed |
| 11 | 39802172 | Omecamtiv mecarbil in precision-cut living heart failure slices: A story of a double-edged sword. | J Mol Cell Cardiol Plus | 2023 | https://conductscience.org/library/papers/39802172 | PubMed |
| 12 | 36672863 | Altered Left Ventricular Rat Gene Expression Induced by the Myosin Activator Omecamtiv Mecarbil. | Genes (Basel) | 2023 | https://conductscience.org/library/papers/36672863 | PubMed |
| 13 | 21616079 | Cardiac myosin activation part 1: from concept to clinic. | J Mol Cell Cardiol | 2011 | https://conductscience.org/library/papers/21616079 | PubMed |
| 14 | 33176437 | Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure: Results From the COSMIC-HF Study. | Circ Heart Fail | 2020 | https://conductscience.org/library/papers/33176437 | PubMed |
| 15 | 21856481 | The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. | Lancet | 2011 | https://conductscience.org/library/papers/21856481 | PubMed |
| 16 | 19234787 | A novel approach to improve cardiac performance: cardiac myosin activators. | Heart Fail Rev | 2009 | https://conductscience.org/library/papers/19234787 | PubMed |
| 17 | 28956314 | New Insights in Cardiac Calcium Handling and Excitation-Contraction Coupling. | Adv Exp Med Biol | 2018 | https://conductscience.org/library/papers/28956314 | PubMed |
| 18 | 27914656 | Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. | Lancet | 2016 | https://conductscience.org/library/papers/27914656 | PubMed |
| 19 | 37239022 | Characterization of Stimulatory Action on Voltage-Gated Na+ Currents Caused by Omecamtiv Mecarbil, Known to Be a Myosin Activator. | Biomedicines | 2023 | https://conductscience.org/library/papers/37239022 | PubMed |
| 20 | 34015475 | Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF. | J Am Coll Cardiol | 2021 | https://conductscience.org/library/papers/34015475 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39802175
GET https://conductscience.org/api/papers/v1/39802175/authors